Spinal Muscular Atrophy: a Timely Review

Overview

Journal Arch Neurol

Specialty Neurology

Date 2011 Apr 13

PMID 21482919

Citations 133

Authors

Stephen J Kolb

John T Kissel

Affiliations

Soon will be listed here.

Abstract

Spinal muscular atrophy (SMA) is a neurodegenerative disease characterized by loss of motor neurons in the anterior horn of the spinal cord and resultant weakness. The most common form of SMA, accounting for 95% of cases, is autosomal recessive proximal SMA associated with mutations in the survival of motor neurons (SMN1) gene. Relentless progress during the past 15 years in the understanding of the molecular genetics and pathophysiology of SMA has resulted in a unique opportunity for rational, effective therapeutic trials. The goal of SMA therapy is to increase the expression levels of the SMN protein in the correct cells at the right time. With this target in sight, investigators can now effectively screen potential therapies in vitro, test them in accurate, reliable animal models, move promising agents forward to clinical trials, and accurately diagnose patients at an early or presymptomatic stage of disease. A major challenge for the SMA community will be to prioritize and develop the most promising therapies in an efficient, timely, and safe manner with the guidance of the appropriate regulatory agencies. This review will take a historical perspective to highlight important milestones on the road to developing effective therapies for SMA.

Citing Articles

Evaluation and Treatment of Thoracic Insufficiency Syndrome and Early-Onset Scoliosis.

Bowen M, Desai V, Anari J, Cahill P J Clin Med. 2025; 14(3).

PMID: 39941426 PMC: 11818242. DOI: 10.3390/jcm14030753.

The association between gait speed and falls in ambulatory adults with spinal muscular atrophy: a retrospective pilot study.

Jira K, Jaworek A, Allen M, Zhao S, Kelly K, Arnold W Front Neurol. 2024; 15:1491466.

PMID: 39697435 PMC: 11652354. DOI: 10.3389/fneur.2024.1491466.

Swallowing function in patients with spinal muscular atrophy before and after the introduction of new gene-based therapies: what has changed?.

Ruggiero M, Giannotta G, Pirani G, Saponaro F, Oliva M, Ferrante C Neurol Sci. 2024; 46(3):1137-1149.

PMID: 39630343 PMC: 11828825. DOI: 10.1007/s10072-024-07883-0.

Respiratory outcomes of onasemnogene abeparvovec treatment for spinal muscular atrophy: national real-world cohort study.

Lavie M, Rochman M, Domany K, Golan Tripto I, Beer M, Besor O Eur J Pediatr. 2024; 184(1):58.

PMID: 39625559 PMC: 11614959. DOI: 10.1007/s00431-024-05886-9.

Copy Number Association with Spinal Muscular Atrophy Severity: Insights from Colombian Patients.

Lamadrid-Gonzalez J, Castellar-Leones S, Contreras-Velasquez J, Bermudez V J Clin Med. 2024; 13(21).

PMID: 39518541 PMC: 11545890. DOI: 10.3390/jcm13216402.

References

Chang J, Hsieh-Li H, Jong Y, Wang N, Tsai C, Li H . Treatment of spinal muscular atrophy by sodium butyrate. Proc Natl Acad Sci U S A. 2001; 98(17):9808-13. PMC: 55534. DOI: 10.1073/pnas.171105098. View

Pellizzoni L . Chaperoning ribonucleoprotein biogenesis in health and disease. EMBO Rep. 2007; 8(4):340-5. PMC: 1852756. DOI: 10.1038/sj.embor.7400941. View

Valori C, Ning K, Wyles M, Mead R, Grierson A, Shaw P . Systemic delivery of scAAV9 expressing SMN prolongs survival in a model of spinal muscular atrophy. Sci Transl Med. 2010; 2(35):35ra42. DOI: 10.1126/scitranslmed.3000830. View

Mailman M, Heinz J, Papp A, Snyder P, Sedra M, Wirth B . Molecular analysis of spinal muscular atrophy and modification of the phenotype by SMN2. Genet Med. 2002; 4(1):20-6. DOI: 10.1097/00125817-200201000-00004. View

Dominguez E, Marais T, Chatauret N, Benkhelifa-Ziyyat S, Duque S, Ravassard P . Intravenous scAAV9 delivery of a codon-optimized SMN1 sequence rescues SMA mice. Hum Mol Genet. 2010; 20(4):681-93. DOI: 10.1093/hmg/ddq514. View

Prior T, Snyder P, Rink B, Pearl D, Pyatt R, Mihal D . Newborn and carrier screening for spinal muscular atrophy. Am J Med Genet A. 2010; 152A(7):1608-16. DOI: 10.1002/ajmg.a.33474. View

Baughan T, Dickson A, Osman E, Lorson C . Delivery of bifunctional RNAs that target an intronic repressor and increase SMN levels in an animal model of spinal muscular atrophy. Hum Mol Genet. 2009; 18(9):1600-11. PMC: 2667287. DOI: 10.1093/hmg/ddp076. View

Foust K, Wang X, McGovern V, Braun L, Bevan A, Haidet A . Rescue of the spinal muscular atrophy phenotype in a mouse model by early postnatal delivery of SMN. Nat Biotechnol. 2010; 28(3):271-4. PMC: 2889698. DOI: 10.1038/nbt.1610. View

Hua Y, Sahashi K, Hung G, Rigo F, Passini M, Bennett C . Antisense correction of SMN2 splicing in the CNS rescues necrosis in a type III SMA mouse model. Genes Dev. 2010; 24(15):1634-44. PMC: 2912561. DOI: 10.1101/gad.1941310. View

10.

Dubowitz V . Infantile muscular atrophy--a broad spectrum. Clin Proc Child Hosp Dist Columbia. 1967; 23(8):223-39. View

11.

Williams J, Schray R, Patterson C, Ayitey S, Tallent M, Lutz G . Oligonucleotide-mediated survival of motor neuron protein expression in CNS improves phenotype in a mouse model of spinal muscular atrophy. J Neurosci. 2009; 29(24):7633-8. PMC: 6665627. DOI: 10.1523/JNEUROSCI.0950-09.2009. View

12.

Prior T, Krainer A, Hua Y, Swoboda K, Snyder P, Bridgeman S . A positive modifier of spinal muscular atrophy in the SMN2 gene. Am J Hum Genet. 2009; 85(3):408-13. PMC: 2771537. DOI: 10.1016/j.ajhg.2009.08.002. View

13.

Wang C, Finkel R, Bertini E, Schroth M, Simonds A, Wong B . Consensus statement for standard of care in spinal muscular atrophy. J Child Neurol. 2007; 22(8):1027-49. DOI: 10.1177/0883073807305788. View

14.

Andreassi C, Jarecki J, Zhou J, Coovert D, Monani U, Chen X . Aclarubicin treatment restores SMN levels to cells derived from type I spinal muscular atrophy patients. Hum Mol Genet. 2001; 10(24):2841-9. DOI: 10.1093/hmg/10.24.2841. View

15.

Lim S, Hertel K . Modulation of survival motor neuron pre-mRNA splicing by inhibition of alternative 3' splice site pairing. J Biol Chem. 2001; 276(48):45476-83. DOI: 10.1074/jbc.M107632200. View

16.

Burghes A, Beattie C . Spinal muscular atrophy: why do low levels of survival motor neuron protein make motor neurons sick?. Nat Rev Neurosci. 2009; 10(8):597-609. PMC: 2853768. DOI: 10.1038/nrn2670. View

17.

Dubowitz V . Ramblings in the history of spinal muscular atrophy. Neuromuscul Disord. 2008; 19(1):69-73. DOI: 10.1016/j.nmd.2008.10.004. View

18.

Dickson A, Osman E, Lorson C . A negatively acting bifunctional RNA increases survival motor neuron both in vitro and in vivo. Hum Gene Ther. 2009; 19(11):1307-15. PMC: 2940461. DOI: 10.1089/hum.2008.067. View

19.

Lefebvre S, Burglen L, Reboullet S, Clermont O, Burlet P, Viollet L . Identification and characterization of a spinal muscular atrophy-determining gene. Cell. 1995; 80(1):155-65. DOI: 10.1016/0092-8674(95)90460-3. View

20.

Coady T, Baughan T, Shababi M, Passini M, Lorson C . Development of a single vector system that enhances trans-splicing of SMN2 transcripts. PLoS One. 2008; 3(10):e3468. PMC: 2565107. DOI: 10.1371/journal.pone.0003468. View